University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Venetoclax + BTKi, Venetoclax + PI3Ki & BTKi + PI3Ki

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Matthew Davids
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Matthew Davids
47 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
CLL Therapy in 2019
13:16
University of Miami's 2nd Biennial Miami Leukemia Symposium

Advances in the CLL Frontline Therapy: BTK Inhibitors vs. Chemoimmun…

Feat. J. Woyach
07:09
University of Miami's 2nd Biennial Miami Leukemia Symposium

The Big Question in CLL Frontline Therapy: How to Choose Between Ibr…

Feat. J. Woyach
24:51
University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Combination Therapies in R/R CLL: Venetoclax +R, Vene…

Feat. M. Davids